Perritt Capital Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-149,463
| Closed | -$1.3M | – | 243 |
|
|
2018
Q2 | $1.3M | Buy |
149,463
+88,016
| +143% | +$792K | 0.38% | 83 |
|
|
2018
Q1 | $581K | Buy |
+61,447
| New | +$516K | 0.17% | 140 |
|
|
2016
Q4 | – | Sell |
-27,950
| Closed | -$155K | – | 231 |
|
|
2016
Q3 | $155K | Sell |
27,950
-86,244
| -76% | -$570K | 0.04% | 214 |
|
|
2016
Q2 | $800K | Buy |
114,194
+44,194
| +63% | +$311K | 0.21% | 114 |
|
|
2016
Q1 | $463K | Sell |
70,000
-3,000
| -4% | -$22.1K | 0.12% | 169 |
|
|
2015
Q4 | $752K | Sell |
73,000
-20,000
| -22% | -$232K | 0.16% | 129 |
|
|
2015
Q3 | $1.1M | Sell |
93,000
-64,382
| -41% | -$712K | 0.23% | 116 |
|
|
2015
Q2 | $1.44M | Buy |
157,382
+2,882
| +2% | +$21.8K | 0.26% | 119 |
|
|
2015
Q1 | $959K | Hold |
154,500
| – | – | 0.17% | 138 |
|
|
2014
Q4 | $865K | Buy |
154,500
+30,800
| +25% | +$179K | 0.16% | 133 |
|
|
2014
Q3 | $729K | Sell |
123,700
-3,700
| -3% | -$22.6K | 0.14% | 153 |
|
|
2014
Q2 | $873K | Sell |
127,400
-500
| -0.4% | -$3.35K | 0.15% | 143 |
|
|
2014
Q1 | $922K | Buy |
127,900
+71,350
| +126% | +$493K | 0.15% | 155 |
|
|
2013
Q4 | $374K | Hold |
56,550
| – | – | 0.06% | 229 |
|
|
2013
Q3 | $411K | Buy |
+56,550
| New | +$381K | 0.08% | 205 |
|
Perritt Capital Management's JNP Position: Q3 2018 in Review
Perritt Capital Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 149,463 shares — an estimated $1.3M sold.
Perritt Capital Management first reported a position in JNP in Q3 2013 and held it in 15 quarters. The position peaked at $1.44M in Q2 2015. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Perritt Capital Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Perritt Capital Management sold 149,463 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $1.3M.
- Perritt Capital Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 15 quarters.
- Perritt Capital Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.44M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Perritt Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.